One of the major research aims in this work has been to examine the possibility that, despite the unchanged protein levels in the APP/PS1 model of AD, GABAB receptors may still undergo changes in their localization along the plasma membrane vs. cytoplasmic sites with pathology progression. This evidence concerns the gene APP and Alzheimer disease.